MEDICURE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1 CAD | -1.96% |
|
-2.91% | -28.57% |
| Apr. 09 | Transcript : Medicure Inc., 2023 Earnings Call, Apr 09, 2024 | |
| Apr. 08 | Medicure Swung to a Loss in 2023 on Lower Sales | MT |
Presentation Operator MessageOperator (Operator)Welcome to Medicure's Q2 Financial Statement E...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Medicure Inc. is a Canada-based pharmaceutical company. The Company is focused on the development and commercialization of therapies for the United States cardiovascular market. The focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Companyâs United States subsidiary, Medicure Pharma Inc. The Company also operates Marley Drug, Inc. (Marley Drug), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
Calendar
2024-05-26
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -28.57% | 7.62M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- MPH Stock
- News Medicure Inc.
- Transcript : Medicure Inc., Q2 2022 Earnings Call, Aug 25, 2022
